目的 探討非小細(xì)胞肺癌（NSCLC）患者外周血液中表皮生長因子受體（EGFR）基因突變與?？颂婺嶂委熜Ч南嚓P(guān)性。方法 選取洛陽市第三人民醫(yī)院自2014年2月-2018年2月收治的101例NSCLC患者作為實(shí)驗(yàn)對象，采用RT-PCR技術(shù)檢測外周血液中EGFR基因突變情況，依據(jù)測定結(jié)果分為基因突變組和野生型組，均采用?？颂婺嶂委煼治銎渲委熜Ч?；選取同期做健康體檢的患者50例作為對照組，比較NSCLC患者與健康人外周血液中EGFR突變差異。結(jié)果 50例健康人外周血液檢測EGFR基因突變率為0，NSCLC患者中EGFR基因突變率為41.58%（42例），EGFR野生型組患者31.68%（32例），EGFR基因未突變者27例?；蛲蛔兘M患者疾病控制率為85.71%，治療有效率為64.29%；野生型組疾病控制率為59.38%，總有效率僅為12.5%，數(shù)據(jù)差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。隨訪6個(gè)月內(nèi)兩組患者生存率差異無統(tǒng)計(jì)學(xué)意義，隨訪1、2年間EGFR基因突變組的生存率均遠(yuǎn)高于野生型組，數(shù)據(jù)差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 NSCLC患者外周血中EGFR基因突變患者行?？颂婺嶂委熜Ч?，因此在晚期的NSCLC患者治療中可以通過測定是否EGFR基因突變來指導(dǎo)靶向藥物治療。

Objective To investigate the relationship between the mutation of epidermal growth factor receptor (EGFR) gene in peripheral blood of patients with non-small cell lung cancer (NSCLC) and the therapeutic effect of Icotinib. Methods 101 cases of NSCLC patients admitted in our hospital from February 2014-2018 February were selected as experimental subjects. RT-PCR technique was used to detect the mutation of EGFR gene in the peripheral blood, and the results were divided into gene mutation group and wild type group according to the results. 50 patients with physical examination were used as control group. The difference of EGFR mutation in peripheral blood between NSCLC patients and healthy persons was compared. Results The mutation rate of EGFR gene was 0 in 50 healthy people. The mutation rate of EGFR gene in NSCLC patients was 41.58% (42 cases), 31.68% (32 cases) in EGFR wild type group and 27 cases of EGFR gene without mutation. The rate of disease control in the gene mutation group was 85.71%, the effective rate was 64.29%, the disease control rate of the wild type group was 59.38%, the total effective rate was only 12.5%, the difference of the data was statistically significant (P<0.05). The survival rate of the two groups in the two groups was not statistically significant during the follow-up period of six months, and the survival rate of the EGFR gene mutation group was followed up for one years and two years. The difference was statistically significant (P<0.05). Conclusion the effect of EGFR gene mutation in peripheral blood of NSCLC patients is more effective, so the targeted drug therapy can be guided by measuring the mutation of EGFR gene in the treatment of advanced NSCLC patients.